<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32092309</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0012</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>158</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gastroenterology</Title>
          <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.</ArticleTitle>
        <Pagination>
          <StartPage>2139</StartPage>
          <EndPage>2149.e14</EndPage>
          <MedlinePgn>2139-2149.e14</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2020.02.030</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(20)30241-9</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS">We evaluated the efficacy and safety of upadacitinib, an oral selective inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC).</AbstractText>
          <AbstractText Label="METHODS">We performed a multicenter, double-blind, phase 2b study of 250 adults with moderately to severely active UC and an inadequate response, loss of response, or intolerance to corticosteroids, immunosuppressive agents, and/or biologic therapies. Patients were randomly assigned to groups that received placebo or induction therapy with upadacitinib (7.5 mg, 15 mg, 30 mg, or 45 mg, extended release), once daily for 8 weeks. The primary endpoint was the proportion of participants who achieve clinical remission according to the adapted Mayo score at week 8. No multiplicity adjustments were applied.</AbstractText>
          <AbstractText Label="RESULTS">At week 8, 8.5%, 14.3%, 13.5%, and 19.6% of patients receiving 7.5 mg, 15 mg, 30 mg, or 45 mg upadacitinib, respectively, achieved clinical remission compared with none of the patients receiving placebo (P = .052, P = .013, P = .011, and P = .002 compared with placebo, respectively). Endoscopic improvement at week 8, defined as endoscopic subscore of ≤ 1, was achieved in 14.9%, 30.6%, 26.9%, and 35.7% of patients receiving upadacitinib 7.5 mg, 15 mg, 30 mg, or 45 mg, respectively, compared with 2.2% receiving placebo (P = .033, P &lt; .001, P &lt; .001, and P &lt; .001 compared with placebo, respectively). One event of herpes zoster and 1 participant with pulmonary embolism and deep venous thrombosis (diagnosed 26 days after treatment discontinuation) were reported in the group that received upadacitinib 45 mg once daily. Increases in serum lipid levels and creatine phosphokinase with upadacitinib were observed.</AbstractText>
          <AbstractText Label="CONCLUSION">In a phase 2b trial, 8 weeks of treatment with upadacitinib was more effective than placebo for inducing remission in patients with moderately to severely active UC. (ClinicalTrials.gov, Number: NCT02819635).</AbstractText>
          <CopyrightInformation>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sandborn</LastName>
            <ForeName>William J</ForeName>
            <Initials>WJ</Initials>
            <AffiliationInfo>
              <Affiliation>University of California San Diego, La Jolla, California. Electronic address: wsandborn@ucsd.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghosh</LastName>
            <ForeName>Subrata</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>National Institute for Health Research Biomedical Research Centre Birmingham, University of Birmingham and University Hospitals Birmingham National Health Service Trust, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Panes</LastName>
            <ForeName>Julian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital Clínic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schreiber</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Haens</LastName>
            <ForeName>Geert</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Amsterdam University Medical Centers, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanida</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Nagoya City University, Nagoya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siffledeen</LastName>
            <ForeName>Jesse</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>University of Alberta, Edmonton, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Enejosa</LastName>
            <ForeName>Jeffrey</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc, North Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc, North Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Othman</LastName>
            <ForeName>Ahmed A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc, North Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Bidan</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc, North Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higgins</LastName>
            <ForeName>Peter D R</ForeName>
            <Initials>PDR</Initials>
            <AffiliationInfo>
              <Affiliation>University of Michigan, Ann Arbor, Michigan. Electronic address: phiggins@med.umich.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02819635</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Gastroenterology</MedlineTA>
        <NlmUniqueID>0374630</NlmUniqueID>
        <ISSNLinking>0016-5085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4RA0KN46E0</RegistryNumber>
          <NameOfSubstance UI="C000613732">upadacitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Gastroenterology. 2021 Apr;160(5):1472-1474</RefSource>
          <PMID Version="1">32311362</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Gastroenterology. 2020 Sep;159(3):1192</RefSource>
          <PMID Version="1">32853541</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005765" MajorTopicYN="N">Gastrointestinal Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">IBD Treatment</Keyword>
        <Keyword MajorTopicYN="Y">Inflammatory Bowel Disease</Keyword>
        <Keyword MajorTopicYN="Y">Selective JAK1 Inhibitor</Keyword>
        <Keyword MajorTopicYN="Y">U-ACHIEVE</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32092309</ArticleId>
        <ArticleId IdType="doi">10.1053/j.gastro.2020.02.030</ArticleId>
        <ArticleId IdType="pii">S0016-5085(20)30241-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
